Article ID Journal Published Year Pages File Type
2143377 Lung Cancer 2009 5 Pages PDF
Abstract

BackgroundThe thyroid transcription factor-1 (TTF-1) is a tissue-specific transcription factor that could play an important role in cell differentiation and morphogenesis of lung tumors. Matrix metalloproteinase-9 (MMP-9) is a protease commonly expressed in non-small cell lung cancer, conferring angiogenic and metastatic potential.MethodsWe assessed TTF-1 and MMP-9 tumor expression by immunohistochemistry in 51 patients with lung adenocarcinoma, stage IIIB or IV, treated with platinum regimens. A bicategorical prognostic model was obtained using the Kaplan–Meier method, Cox regression, and conjunctive consolidation.ResultsThe median expression of TTF-1 was 30.0% (range: 0–85.9%). All tumors expressed MMP-9 (median: 78.7%; range: 15.2–96.1%). Median survival was 41.6 weeks, with estimated 1- and 2-year survival rates of 45.0% and 22.0%, respectively. Poor performance status (Karnofsky scale) – hazards ratio (HR): 1.03, 95% confidence interval (CI): 1.01–1.06; low TTF-1 expression (<40%) – HR: 4.00, 95% CI: 1.75–9.09; and high MMP-9 expression (≥80%) – HR: 2.82, 95% CI: 1.30–6.08 were independent prognostic factors. Patients could be stratified in three death risk groups according to markers expression: low risk (high TTF-1 and low MMP-9; median survival: 127.6 weeks), intermediate risk (low TTF-1 or high MMP-9; median survival: 39.0 weeks); and high risk (low TTF-1 and high MMP-9; median survival: 16.4 weeks).ConclusionTTF-1 and MMP-9 tumor expression as detected by immunohistochemistry may allow identification of different, clinically meaningful, prognostic groups of advanced lung adenocarcinoma patients treated with platinum regimens.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , ,